Biotech company Prescient Therapeutics has now opened its Share Purchase Plan (SPP) to raise up to A$7 million - which will go toward ongoing Phase 2 trials of PTX-100, a targeted cancer therapy aimed at treating Cutaneous T-Cell Lymphoma.
Shares will be priced at 4 cents - representing a 16.7% discount to the 15-day volume weighted average price of Prescient.
Prescient's PTX-100 has already obtained Orphan Drug and Fast Track designations from the United States Food and Drug Administration (FDA) and has demonstrated promising safety and efficacy in prior studies.
#Biotech #CancerResearch #ClinicalTrials #PrescientTherapeutics #PTX100 #SharePurchasePlan #ASXNews #OrphanDrug #FastTrackFDA #CutaneousTCellLymphoma #TargetedTherapy #OncologyInnovation #InvestorUpdate #AustralianBiotech #SPP2025